This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
This intro compares merchant acceptance for BTC and ETH, outlining where each is more commonly accepted by merchants.
27,224 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
A new Ipsos poll reveals growing World Cup enthusiasm among U.S. fans while broad adoption lags. The findings hint at...
Gas lines, higher prices, and tighter budgets define daily life as Russia’s fuel crisis unfolds across regions. This ...
Investors are turning to dividend-growth stocks to build a rising income stream that can outpace inflation over a dec...
Asia’s aging demographics are fueling a surge in high-end longevity clinics and wellness residencies, creating new op...
A new global liveability ranking places a major city at the bottom in 2026, triggering concerns about investment, hou...
Cheyenne authorities blame Meta’s in-progress data center for contaminating part of the city’s reclaimed water. The i...
Colorado unveils a sweeping plan to fix the battery recycling economics problem by funding a statewide recycling prog...
Bitcoin has pulled back sharply from recent highs, leaving both new and seasoned investors wondering what comes next....
The YieldMax COIN Option Income Strategy ETF, ticker CONY, endured a steep 56.25% decline in the latest year, with di...
SpaceX isn’t your typical public stock, but the question remains: should spacex stock below the IPO price be a buying...
When a public figure shares rare childhood memories, it can feel personal. This piece translates that moment into act...